Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes

被引:71
作者
Miyata, T [1 ]
Devuyst, O
Kurokawa, K
de Strihou, CV
机构
[1] Tokai Univ, Sch Med, Inst Med Sci, Isehara, Kanagawa 2591143, Japan
[2] Tokai Univ, Sch Med, Dept Internal Med, Isehara, Kanagawa 2591143, Japan
[3] Catholic Univ Louvain, Serv Nephrol, Brussels, Belgium
关键词
ultrafiltration failure; effective peritoneal surface area; angiogenesis; nitric oxide; vascular endothelial growth factor; carbonyl stress; advanced glycation end products; glucose degradation products;
D O I
10.1046/j.1523-1755.2002.00135.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Peritoneal dialysis (PD) has modified our concept of the peritoneal membrane, which is now a topic of active research. Peritoneal solute transport progressively increases with time on PD, enhances the dissipation of the osmotic gradient and, eventually, reduces ultrafiltration capacity. The causes of peritoneal membrane failure remain elusive. Recurrent episodes of peritonitis are not a prerequisite for the development of ultrafiltration failure. Functionally, the changes of the failing peritoneal membrane are best described as an increased functional area of exchange for small solutes between blood and dialysate. Histologically, these events are associated with vascular proliferation and structural changes of pre-existing vessels. Gathered evidence, including information on the composition of peritoneal cavity fluids and its dependence on the uremic environment, have cast a new light on the molecular mechanisms of decline in peritoneal membrane function. Chronic uremia per se modifies the peritoneal membrane and increases the functional area of exchange for small solutes. Biochemical alterations in the peritoneum inherent to uremia might be, at least in part, accounted for by severe reactive carbonyl compounds overload originating both from uremic circulation and PD fluid ("peritoneal carbonyl stress"). The molecular events associated with long-term PD are similar but more severe than those present in chronic uremia without PD, including modifications of nitric oxide synthase (NOS) and angiogenic growth factors expression, and advanced glycation and lipoxidation of the peritoneal proteins. This review focuses on reactive carbonyls and their association with a number of molecular changes observed in peritoneal tissues. This hypothetical approach will require further testing. Nevertheless, the insights gained on the peritoneal membrane offer a new paradigm to assess the effect of uremic toxins on serosal membranes. Furthermore, the progresses made in the dissection of the molecular events leading to peritoneal membrane failure open new avenues to develop safe, more biocompatible peritoneal dialysis technologies.
引用
收藏
页码:375 / 386
页数:12
相关论文
共 118 条
[31]  
Griffioen AW, 2000, PHARMACOL REV, V52, P237
[32]   Increased aggregation of human platelets produced by advanced glycation end products in vitro [J].
Hangaishi, M ;
Taguchi, J ;
Miyata, T ;
Ikari, Y ;
Togo, M ;
Hashimoto, Y ;
Watanabe, T ;
Kimura, S ;
Kurokawa, K ;
Ohno, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (02) :285-292
[33]  
Hayashi T, 1986, DEV FOOD SCI, P29
[34]   S-nitrosylation: spectrum and specificity [J].
Hess, DT ;
Matsumoto, A ;
Nudelman, R ;
Stamler, JS .
NATURE CELL BIOLOGY, 2001, 3 (02) :E46-E49
[35]   Inhibition of nitric oxide synthase as a potential therapeutic target [J].
Hobbs, AJ ;
Higgs, A ;
Moncada, S .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :191-220
[36]  
HodacPannekeet MM, 1996, PERITON DIALYSIS INT, V16, P255
[37]   Genetic modification of the peritoneal membrane: Potential for improving peritoneal dialysis through gene therapy [J].
Hoff, CM ;
Shockley, TR .
SEMINARS IN DIALYSIS, 1998, 11 (04) :218-227
[38]   Ex vivo and in vivo gene transfer to the peritoneal membrane in a rat model [J].
Hoff, CM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (03) :666-668
[39]   β2-microglobulin modified with advanced glycation end products delays monocyte apoptosis [J].
Hou, FF ;
Miyata, T ;
Boyce, J ;
Yuan, Q ;
Chertow, GM ;
Kay, J ;
Schmidt, AM ;
Owen, WF .
KIDNEY INTERNATIONAL, 2001, 59 (03) :990-1002
[40]   Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis [J].
Inagi, R ;
Miyata, T ;
Yamamoto, T ;
Suzuki, D ;
Urakami, K ;
Saito, A ;
de Strihou, CV ;
Kurokawa, K .
FEBS LETTERS, 1999, 463 (03) :260-264